

Applicants : Jacob Bar-Tana and Ihor Bekersky
Serial No. : 10/585,017
Filed : June 28, 2008
Page 12 of 14: Amendment in Response to July 6, 2010 Office
Action, Supplemental Information Disclosure
Statement and Petition for a Three-Month
Extension of Time

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following references, which are listed on the PTO-1449 Substitute form attached hereto as **Exhibit A**. Item 1 is a Supplementary European Search Report corresponding to a counterpart European Application. Items 2-6 were cited in item 1.

Items 2-3 are U.S. Patents, and in accordance with 37 C.F.R. §1.98(a)(2)(ii) copies of these items are not attached. Copies of items 1 and 4-6 are attached hereto as **Exhibits B-E**, respectively:

1. October 4, 2010 Supplementary European Search Report issued in connection with European Application No. EP 04 80 6716 (**Exhibit B**);
2. U.S. Patent No. 4,634,795, issued January 6, 1987 (Bar-Tana);
3. U.S. Patent No. 4,711,896, issued December 8, 1987 (Bar-Tana et al.);
4. PCT International Application Publication No. WO 99/00116 A2, published January 7, 1999 (Bar-Tana) (**Exhibit C**);
5. Russell et al., "Inhibition of atherosclerosis and myocardial lesions in the JCR:LA-cp rat by β,β' -tetramethylhexadecanedioic acid (MEDICA 16), Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15., no. 7, 1995 (**Exhibit D**); and

Applicants : Jacob Bar-Tana and Ihor Bekersky
Serial No. : 10/585,017
Filed : June 28, 2008
Page 13 of 14: Amendment in Response to July 6, 2010 Office
Action, Supplemental Information Disclosure
Statement and Petition for a Three-Month
Extension of Time

6. McCarty, M.F., "Peroxisome proliferators as adjuvants for the reverse-electron-transport therapy of obesity: An explanation for the large increase in metabolic rate of MEDICA 16-treated rats," *Medical Hypotheses*, vol. 53, no. 4, 1999 (**Exhibit E**).


According to 37 C.F.R. § 1.97(c), a Supplemental Information Disclosure Statement filed after the period specified in 37 C.F.R. § 1.97(b) shall be considered if accompanied by the fee set forth in 37 C.F.R. § 1.17(p) or a statement under 37 C.F.R. § 1.97(e). The required fee set forth in 37 C.F.R. § 1.97(p) is ONE HUNDRED EIGHTY DOLLARS (\$180.00) and authorization is given to charge this fee to Deposit Account No. 03-3125.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.


Applicants : Jacob Bar-Tana and Ihor Bekersky
Serial No. : 10/585,017
Filed : June 28, 2008
Page 14 of 14: Amendment in Response to July 6, 2010 Office
Action, Supplemental Information Disclosure
Statement and Petition for a Three-Month
Extension of Time

No fee, other than the total fee of \$735.00 (\$555.00 for a Three-Month Extension of Time and \$180.00 fee for filing a Supplemental Information Disclosure Statement), is deemed necessary in connection with the filing of this Amendment in Response to July 6, 2010 Office Action, Supplemental Information Disclosure Statement and Petition for a Three-Month Extension of Time. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
30 Rockefeller Plaza
20th Floor
New York, New York 10112
(212) 278-0400

Certificate of Transmission	
I hereby certify that this correspondence is being transmitted via the Electronic Filing System (EFS) to the U.S. Patent and Trademark Office on <u>January 6, 2011</u> .	
 Adam C. Krol Reg. No. 64,351	<u>1/6/11</u> Date